Drug Type Therapeutic vaccine, mRNA vaccine |
Synonyms |
Target |
Action stimulants, agonists |
Mechanism RIG-I stimulants(Retinoic acid-inducible gene I stimulants), TLR7 agonists(Toll like receptor 7 agonists), TLR8 agonists(Toll like receptor 8 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Phase 2 | United Kingdom | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | United Kingdom | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | Belgium | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | Italy | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | Belgium | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | Italy | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | Germany | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | Spain | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | Spain | 18 Sep 2017 | |
Hepatocellular Carcinoma | Phase 2 | Germany | 18 Sep 2017 |
Phase 1 | 40 | (gnvcxzrzbc) = fxbcaswaej tjrmuufcdu (tqyosikpkb ) | Positive | 11 Nov 2022 | |||
anti-PD-1 antibodies+CV8102 | (gnvcxzrzbc) = scxqfvrlqa tjrmuufcdu (tqyosikpkb ) | ||||||
Phase 1/2 | 22 | oawphlxjzj(pubhfqvpkt) = against ≥1 vaccinated HLA class I tumor-associated peptide (TAA) and ≥1 vaccinated HLA class II TAA were respectively induced in 37% and 53% of the vaccinees yrvcssvrme (pfpqfuuuvt ) View more | Positive | 13 Jun 2022 | |||
Phase 1 | 58 | (fkibhvswok) = lqnnhfirbf eqsfwzlovp (drjnxvgpga ) View more | Positive | 16 Sep 2021 | |||
anti-PD-1 antibodies+CV8102 | (fkibhvswok) = otloaaccar eqsfwzlovp (drjnxvgpga ) View more |